PMGC Holdings (ELAB) Capital Expenditures (2022 - 2026)
PMGC Holdings (ELAB) posted Capital Expenditures of $363087.0 for Q1 2026, up 4.74% sequentially from $346661.0 in Q4 2025.
PMGC Holdings (ELAB) Capital Expenditures (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Capital Expenditures for 5 years, with the latest figure at $363087.0 in Q1 2026.
- Quarterly Capital Expenditures changed N/A year-over-year to $363087.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $709748.0 (changed N/A YoY) and the FY2025 annual result came in at $442255.0, up 4728.11% from the prior year.
- Capital Expenditures rose to $363087.0 in Q1 2026 per ELAB's latest filing, from $346661.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $363087.0 in Q1 2026 and troughed at -$36.9 million in Q4 2022.
- A 5-year average of -$7.2 million and a median of $11191.0 in 2023 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 18.15% in 2024, down 18.15% in 2024.
- Over 5 years, Capital Expenditures stood at -$36.9 million in 2022, then soared by 100.03% to $11191.0 in 2023, then retreated by 18.15% to $9160.0 in 2024, then surged by 3684.51% to $346661.0 in 2025, then grew by 4.74% to $363087.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $363087.0, $346661.0, and $9160.0 for Q1 2026, Q4 2025, and Q1 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.20 Bn | 131.35 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.09 Bn | 78.10 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.04 Bn | 9.65 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.50 Bn | - | 251.02 Mn |
| 10 | PMGC Holdings | 31.45 Mn | 12.66 Mn | 385,691.00 | -27,569.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 363,087.00 |
| Mar 31, 2026 | 363,087.00 |
| Dec 31, 2025 | 346,661.00 |
| Dec 31, 2025 | 346,661.00 |
| Mar 31, 2024 | 9,160.00 |
| Mar 31, 2024 | 9,160.00 |
| Mar 31, 2023 | 11,191.00 |
| Mar 31, 2023 | 11,191.00 |
| Dec 31, 2022 | -36.89 Mn |
| Dec 31, 2022 | -36.89 Mn |